3.Changes in plasma monocyte chemoattractant protein-1 in patients with acute coronary syndrome and patients with restenosis after angioplasty
Jie YU ; Jieming MAO ; Guang WANG
Chinese Journal of Tissue Engineering Research 2007;0(04):-
AIM: To observe acute coronary syndrome (ACS), including acute myocardial infarction (AMI), and unstable angina pectoris (UAP) and plasma monocyte chemoattractant protein-1 (MCP-1) in patients with restenosis after angioplasty, and compared with normal controls. METHODS: Sixty-eight patients were selected from the Department of Cardiology, Third Hospital Affiliated to Peking University between December 2005 and April 2006, including 30 patients with AMI, 20 patients with UAP and 16 patients with restenosis after angioplasty. Thirty healthy people were selected simultaneously to be the controls. All subjects knew and agreed with the items. The level of blood lipid was determined in all enrolled subjects: ① Blood sample was obtained from the elbow of patients with AMI immediately at hospitalization (2-12 hours from onset). ② Blood sample was obtained from patients of UAP group and patients of restenosis after angioplasty group immediately after the hospitalization (within 24 hours of onset). ③ Blood sample was obtained from fasting subjects of the normal control group in the morning. Blood sample was centrifuged, separated of the plasma and then frozen at -70 ℃. The level of plasma MCP-1 was determined with ELISA for statistical analysis. RESULTS: A total of 98 enrolled subjects were involved in the analysis of results, and no one withdrew from the study. Comparison in plasma MCP-1 among all groups: The plasma MCP-1 in ACS group, UAP group and restenosis after angioplasty group were (166.7?46.5,149.4?54.9,119.7?25.0,89.2?26.4) ng/L respectively, and it was significantly higher in ACS group, UAP group and restenosis after angioplasty group than that in the normal control group (F =21.27,P
7.A Follow-up Study of the Relationship between Endothelial Function and Insulin Resistance,Metabolic Syndrome in Obese Subjects
Lu-Yun ZHU ; Li-Ye HU ; Guang-Yu WANG
Chinese Journal of Prevention and Control of Chronic Diseases 2006;0(06):-
Objective To investigate the relationship between vascular endothelial function and insulin resistance(IR) and the incidence of metabolic syndrome(MS).Methods A seven-year follow-up study was conducted in 583 simple obese subjects who were chosen in 2000.Body fat,blood pressure,lipid profile,plasma glucose,insulin resistance index(HOMA-IR) and endothelium- dependent dilatation(EDD) were measured before and after the follow-up.Results A total of 177 new cases with MS were found during this seven years,which was 33.78% of all subjects who were followed up in 2007.Cumulative incidence of MS among seven-year was 38.14% in the impaired EDD group and 48.11% in the impaired EDD with IR group,both rates were higher than that of the IR group(25.00%)(P
8.APPLICATION OF CELL ENZYME IMMUNOASSAY FOR DETECTION AND ANALYSIS OF MONOCLONAL ANTIBODIES TO HUMAN COLORECTAL ADENOCARCINOMA
Jun WANG ; Caixia LIN ; Hui YU ; Guang LI
Chinese Journal of Immunology 1985;0(02):-
A solid-phase cell enzyme-linked immunoassay is described for screeningand analyzing monoclonal antibodies against the cell surface antigensof human colorectal adenocarcinoma.Horse-radish peroxidase conjugatedProtein A was used to detect the binding of mouse monoclonal antibodiesto human colorectal adenocarcinoma.HR_(8348) cells which had been cultured inand then fixed to the wells of microtiter plates by using glutaraldehyde.Thismethod was found to be specific,reproducible and practical,and especiallyto be advantageous for the large scale screening and analyzing of monoclo-nal antibodies with a panel of cell types.
10.Effect of daidzein on hepatocellular carcinoma SMMC7721 cell proliferation and tumor stem cell CD133 expression
Min ZHANG ; Hongzhi SUN ; Wei WANG ; Guang BAI ; Xiaodong YU
Chinese Journal of Biochemical Pharmaceutics 2014;(3):28-30
Objective To discuss the effect of daidzein on hepatocellular carcinoma SMMC7721 cell proliferation CD133 expression on tumor stem cell.Methods Hepatocellular carcinoma SMMC7721 cells were cultured,digested and passaged,and divided into six groups with different drug:control group with no daidzein,100 μg/mL daidzein group,200μg/mL daidzein group,300μg/mL daidzein group,400μg/mL daidzein group ,500μg/mL daidzein.The inhibition ratio,hexokinase,alkaline phosphatase and CD133 levels in SMMC7721 cell were detected and compared at 24 h,48 h,72 h among those groups. Results The inhibition ratio was increased by Daidzein dose increasing,and decreased apparently by times extending,especially in 400μg/mL and 500μg/mL daidzeingroups.Compared with control group,the hexokinase and alkaline phosphatase activity and CD133 expression were decreased apparently in groups treated with daidzein(P<0.01).The more the dose,the higher the drop(P<0.01).Conclusion Daidzein can inhibit hepatocellular carcinoma SMMC7721 cell proliferation,and inhibit CD133 expression on tumor stem cell.